Cell-based immunotherapy for lymphoid malignancies has gained increasing attention as patients develop resistance to conventional treatments. cd T cells, which have major histocompatibility complex (MHC)-unrestricted lytic activity, have become a promising candidate population for adoptive cell transfer therapy. We previously established a stable condition for expanding cd T cells by using anti-cd T-cell receptor (TCR) antibody. In this study, we found that adoptive transfer of the expanded cd T cells to Daudi lymphoma-bearing nude mice significantly prolonged the survival time of the mice and improved their living status. We further investigated the characteristics of these antibody-expanded cd T cells compared to the more commonly used phosphoantigen-expanded cd T cells and evaluated the feasibility of employing them in the treatment of lymphoid malignancies. Slow but sustained proliferation of human peripheral blood cd T cells was observed upon stimulation with anti-cd TCR antibody. Compared to phosphoantigen-stimulated cd T cells, the antibody-expanded cells manifested similar functional phenotypes and cytotoxic activity towards lymphoma cell lines. It is noteworthy that the anti-cd TCR antibody could expand both the Vd1 and Vd2 subsets of cd T cells. The in vitro-expanded Vd1 T cells displayed comparable tumour cell-killing activity to Vd2 T cells. Importantly, owing to higher C-C chemokine receptor 4 (CCR4) and CCR8 expression, the Vd1 T cells were more prone to infiltrate CCL17-or CCL22-expressing lymphomas than the Vd2 T cells. Characterizing the peripheral blood cd T cells from lymphoma patients further confirmed that the anti-cd TCR antibody-expanded cd T cells could be a more efficacious choice for the treatment of lymphoid malignancies than phosphoantigen-expanded cd T cells.
INTRODUCTION
Conventional therapeutic strategies, including chemotherapy and radiotherapy, effectively suppress lymphoid malignancies during the initial treatments. However, the majority of patients become resistant to these therapies. Therefore, other therapeutic strategies, such as cellbased immunotherapy, are attracting increasing attention. 1 Innate immune cells are promising candidates for tumour immunotherapy because they play a critical role in tumour immunosurveillance. 2 cd T cells, which function in both innate and acquired immunity, are considered to be potent candidates for immunotherapy. 3, 4 Unlike conventional ab T cells, cd T cells can be activated and expanded by several phosphorylated non-peptide antigens (phosphoantigens), including isopentenyl pyrophosphate, bromohydrin pyrophosphate, (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate and aminobisphosphonates. 5 Phosphoantigen-activated cd T cells have already been tested in several clinical trials. Considerable anti-tumour effects were often obtained without any significant toxicity. In some clinical trials, the cd T-cell population was increased through in vivo cd T-cell expansion upon phosphoantigen administration. Studies in patients with solid tumours have demonstrated that treatment with bromohydrin pyrophosphate (IPH1101) in combination with low-dose interleukin 2 (IL-2) is safe and well-tolerated and induces potent cd T lymphocyte expansion in patients. 6 In another clinical trial, in patients with advanced breast cancer treated with zoledronate and IL-2, a statistically significant correlation between clinical outcome and peripheral Vc9Vd2 T cell numbers emerged. 7 In addition, the direct transfer of in vitro-expanded cd T cells has been used in some clinical trials and was proven to be safe. [8] [9] [10] In a trial of adoptive transfer of in vitroexpanded cd T cells to non-small cell lung cancer patients, immunomonitoring data showed that the number of peripheral cd T cells gradually increased with increasing numbers of infusions.
upon cd T-cell transfer, [8] [9] [10] even the complete remission of lung metastasis appeared following adoptive immunotherapy with activated autologous cd T cells in a patient with renal cell carcinoma. 11 However, the number of participants in these studies was low, and the anti-tumour effect remains to be confirmed in further studies using larger numbers of participants.
It should be noted that phosphoantigens can only activate and expand the Vd2 subset, while the Vd1 subset, another major population of circulating human cd T cells, cannot be expanded. It is generally accepted that Vd2 T cells, which circulate in the peripheral blood, have the capacity to kill lymphoma and myeloma cells, while Vd1 T cells, which are mainly located in the mucosa-associated lymphoid tissue, possess the function of defending against epithelial cancers.
12, 13 However, several studies have suggested that Vd1 T cells also play a role in defending against lymphoid malignancies. Vd1 T cells have been frequently found in lymphoma tissues and have demonstrated cytotoxicity against stress-associated antigens, such as major histocompatibility complex class I-related chain molecules A and B (MICA/B) and unique long 16-binding proteins (ULBPs)-expressing tumour cells. 14, 15 Herein, we have used an anti-cd T-cell receptor (TCR) antibody (Ab) to expand cd T cells. As previously reported, expansion of only the Vd2 subset occurred upon stimulation with phosphoantigens. In contrast, the anti-cd TCR Ab caused expansion of both the Vd1 and Vd2 subsets of cd T cells. Notably, the expanded Vd1 T cells manifested an enhanced migration tendency towards several lymphoid malignancies compared to Vd2 T cells. Our results indicate a nonredundant role of Vd1 T cells in anti-lymphoma immunotherapy. As a consequence, Ab-expanded cd T cells may have an intrinsic advantage over phosphoantigen expanded cd T cells in the treatment of certain lymphoid malignancies.
MATERIALS AND METHODS

Cell lines
The human tumour cell lines Daudi (Burkitt's lymphoma cell line), Ramos (RA.1, Burkitt's lymphoma cell line), HuT-78 (cutaneous T lymphoma cell line), Jurkat (T cell lymphoma cell line), K562 (chronic myelogenous leukaemia cell line) and RPMI 8226 (myeloma cell line) were obtained from the Cell Culture Center, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (Beijing, China). The L-428 (human Hodgkin's lymphoma cell line) was kindly provided by Professor Xiangmin Tong (Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China). All of the tumour cell lines were maintained in RPMI 1640 medium (Gibco, Gaithersburgh, MD, USA) supplemented with 10% foetal calf serum (FCS; Gibco).
Mice
Athymic BALB/c nu/nu mice (female, 4-6 weeks old) were purchased from the Laboratory Animal Center of the Chinese National Institute for the Control of Pharmaceutical and Biological Products. Mice were maintained in specific pathogen-free conditions at the Animal Maintenance Facility of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences. All animal experiments were carried out in compliance with the animal ethics regulations of Chinese Academy of Medical Sciences.
Patients
Twelve lymphoma patients who had been diagnosed with lymphoma at Peking Union Medical College Hospital were enrolled. Clinical information, including age, gender, diagnosis, Ann Arbor stage at presentation and International Prognostic Index, was collected and listed in Table 1 . The study was approved by the ethical committee of Peking Union Medical College Hospital. Informed consent was obtained from every subject.
Expansion of cd T cells in vitro
Peripheral blood mononuclear cells (PBMCs) were isolated by Ficoll-Hypaque (TBD, Tianjin, China) centrifugation. The expansion of cd T cells was performed as previously described. 16 Briefly, 24-well plates were coated with 500 ml purified anti-cd TCR Ab (IMMU510, 1 mg/ml; Immunotech, Beckman Coulter, Fullerton, CA, USA) at 37 uC for 2 h. Then PBMCs were added to the Abcoated wells and cultured in RPMI 1640 medium supplemented with 10% FCS and 200 IU/ml recombinant human IL-2 (Beijing Read United Cross Pharmaceutical Co., Ltd, Beijing, China). The culture medium was replaced every other day. Alternatively, PBMCs were stimulated with 10 mM pamidronate (PAM) disodium (Aredia, Novartis, Switzerland) and cultured in the same culture 4 IU) or phosphate-buffered saline (PBS) (n58 for each group). IL-2 was given on the day of cell transfer, and administration was continued twice daily for 4 days. Body weight and survival rate were measured every other day. After 48 days of treatment, two mice from each group were killed. Blood films and bone marrow smears were prepared, fixed using absolute methanol, stained with May-Grunwald-Giemsa stain and evaluated by light microscopy for the presence of lymphoma cells. A manual differential count was performed for each blood film by counting 200 white blood cells per film. Lymphoma cells which have a large size, irregular nucleus shape and dark-purple cytoplasm, were included in the differential counts. A differential count was also performed by counting 1000 nucleated cells from each bone marrow smears.
Chemotaxis assays
Chemotaxis assays were performed using 5-mm pore polycarbonate filters in 24-well transwell chambers (Costar; Corning, Lowell, MA, USA). Briefly, RPMI 1640 (600 ml) containing 0.5% bovine serum albumin and rhCCL17 (1 mg/ml; R&D System, Minneapolis, MN, USA) or rhCCL22 (1 mg/ml; R&D System) was added to the bottom chamber of the transwell. Human cd T cells (1310 6 ) suspended in 200 ml RPMI 1640 containing 0.5% bovine serum albumin were placed in the upper wells. In some experiments, cd T cells were pre-incubated with anti-C-C chemokine receptor (CCR4) Ab (1 mg/1310 6 cells; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or anti-CCR8 Ab (1 mg/1310 6 cells; Santa Cruz Biotechnology) for 1 h at room temperature before being placed in the upper wells. The chambers were incubated at 37 uC, 5% CO 2 for 4 h. At the end of the incubation, the cells that migrated into the lower chambers and those left in the upper chambers were collected separately, stained with PE-anti-CD3 and FITC-anti-TCR Vd1 or FITC-anti-TCR Vd2, and analysed by flow cytometry using a FACScan flow cytometer (BD, San Jose, CA, USA). The chemotaxis index was calculated as the ratio of cells migrating towards the chemokine and untreated cells randomly migrating across the membrane.
Flow cytometry
Cells were washed with PBS containing 1% bovine serum albumin and incubated with surface-staining antibodies. After incubation at 4 uC for 20 min, cells were washed and resuspended in 300 ml PBS containing 1% formaldehyde. For intracellular staining, cells were incubated with 20 ng/ml phorbol 12-myristate-13-acetate (PMA; Sigma, St Louis, MO, USA), 0.5 mg/ml ionomycin (Sigma) and 3 mg/ml Brefeldin A (eBioscience, San Diego, CA, USA). After 6 h, the cells were collected and stained for surface markers. Next, cells were fixed, permeabilized, incubated with intracellular antibodies and measured by flow cytometry using a FACScan flow cytometer. Analysis of the FACS data was performed using FlowJo software (Version 5.7.2; Tree Star, Inc., Ashland, OR, USA). The following antibodies, purchased from Immunotech, were used for staining: FITC-conjugated anti-cd TCR (IMMU510), PE-conjugated anti-cd TCR (IMMU510), PEconjugated anti-ab TCR (BMA031), FITC-conjugated anti-TCR Vd2 (IMMU389), PE-conjugated anti-CD3 (IM1282U) and the respective isotype control monoclonal antibodies. PE-conjugated antiinterferon (IFN)-c (4S.B3) and FITC-conjugated anti-granzyme B (GB11) were purchased from BD Pharmingen (San Diego, CA, USA). PE-conjugated anti-CD6 (BL-CD6), tumour-necrosis factor (TNF)-a (MAb11), CD27 (O323), CD107a (H4A3), TNFrelated apoptosis-inducing ligand (TRAIL) (RIK-2), APC-conjugated CD45RA (HI100), NKG2D (1D11), programmed-death receptor 1 (PD1) (12.2H7) and PerCP-cy5.5-conjugated CCR4 (TG6/CCR4) were purchased from BioLegend (San Diego, CA, USA). FITC-conjugated TCR Vd1 (TS8.2) was purchased from Pierce (Rockford, IL, USA). Purified anti-CCR4 and anti-CCR8 antibodies were products of Santa Cruz Biotechnology.
Cell sorting
After 2 weeks in culture, cd T cells were collected and labelled with FITC-conjugated anti-TCR Vd1 or FITC-conjugated anti-TCR Vd2 antibodies and anti-FITC MicroBeads (Miltenyi, Bergisch Gladbach, Germany). Subsequent positive selection was carried out using MS columns (Miltenyi) according to the manufacturer's protocol. Isolated cd T cells were cultured in RPMI 1640 medium supplemented with 10% FCS and 200 IU/ml rhIL-2. After 72 h of rest, cells were collected and used for cytotoxicity assays.
Cytotoxicity assays
The CytoTox 96 H Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI, USA), based on the colorimetric detection of the released lactate dehydrogenase, was used. Tumour cells used as target cells were seeded into a 96-round well plate (5310 4 cells per well). Expanded cd T cells served as effector cells were directly added to individual wells at different effector/target (E/T) ratios. The plate was incubated at 37 uC for 4 h, the supernatants were collected and the lactate dehydrogenase activity was detected. Controls for spontaneous lactate dehydrogenase release from effector and target cells, the target maximum release, as well as the culture medium background were assayed simultaneously. The cytotoxicity was calculated as follows: %CytotoxicityẼ xperimental{Effector spontaneous{Target spontaneous Target maximum{Target spontaneous |100%
Reverse transcription-polymerase chain reaction (PCR) Total RNA was extracted from distinct tumour cell lines with the RNeasy Mini Kit (QIAGEN, Hilden, Germany). cDNA was synthesized using oligo-dT as primers and the Moloney murine leukaemia virus reverse transcriptase (Promega) in the reverse transcription reaction, and sequences were amplified by polymerase chain reaction using the following primers. b-ACTIN: forward: 59-ACTGTGCCCATCTACGAGGG-39; reverse: 59-GTGGTGGTGAAGCTGTAGCC-39; CCL17: forward: 59-CCTGGTCACCCTCCTCCTG-39; reverse: 59-GGTACCACGTCTTCAGCTTTCT-39; CCL22: forward: 59-GTTGTCCTCGTCCTCCTTGC-39; reverse: 59-GGAGTCTGAGGTCCAGTAGAAGTG-39. Real-time PCR was performed in an Applied Biosystems 7500 Fast Real Time PCR System to quantify the levels of CCL17 and CCL22 mRNA. The amplification reaction was performed in a volume of 20 ml, containing oligonucleotide primers (5 mM each) and SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, Adoptive cd T cell Immunotherapy JH Zhou et al 36 USA), which contained Taq DNA Polymerase, the reaction buffer, dNTP and the double-stranded DNA-specific fluorescent dye SYBR Green. The amplification reaction was carried out using the following two-step procedure: denaturation at 95 uC for 10 min and 40 cycles with denaturation at 95 uC for 15 s, and annealing and elongation at 60 uC for 1 min. The fluorescent signal from the samples was measured at the end of the elongation step. The results were analysed using Sequence Detection Software (version 1.2; Applied Biosystems) and reported as the relative ratios to the expression levels in Jurkat cells.
Enzyme-linked immunosorbent assay (ELISA)
Tumour cells ( 5310 5 ) in 500 ml RPMI 1640 supplemented with 10% FCS were seeded in 24-well plates and cultured for 48 h. Next, the cell culture supernatants from each well were collected to measure chemokine concentration. Quantikine Human TARC/CCL17 ELISA Kits and Quantikine Human MDC/CCL22 ELISA Kits (R&D Systems) were used to quantify thymus and activation-regulated chemokine (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22) levels in tumour cell culture supernatants. The assay procedure was performed according to the manufacturer's instructions. The optical density in each well was determined within 30 min using a microplate reader set at the spectrum of 450 nm with l correction at 570 nm.
Statistical analysis
Data are presented as mean6s.d. The comparisons of quantitative data between two groups were performed by Student's t-test. Repeated-measures analysis of variance followed by least significant difference was used to compare the mouse weights. The log-rank test was used in Kaplan-Meier survival analysis. A P value of less than 0.05 was considered statistically significant.
RESULTS
Anti-lymphoma effect of Ab-expanded cd T cells in vitro and in vivo Anti-tumour efficacy is an important parameter for successful adoptive immunotherapy. We examined the cytotoxicity of Ab-expanded cd T cells towards various haematological tumour cell lines. Ex vivoexpanded cd T cells showed potent cytotoxicity against all of the tested lymphoma cell lines, including Daudi, Ramos (RA.1), HuT-78, Jurkat and L-428, as well as against the chronic myelogenous leukaemia cell line K562 and the myeloma cell line RPMI 8226 (Figure 1a) .
To determine the anti-tumour efficacy of adoptively transferred cd T cells, Daudi lymphoma-bearing nude mice were treated with cd T cells plus IL-2, IL-2 alone or PBS. As shown in Figure 1b , the survival rate of mice treated with cd T cells plus IL-2 was significantly higher than the PBS-or IL-2-treated group, as was the change in body weight (Figure 1c) . Lymphoma cells were not observed in the murine blood films from any of the tested groups. Whereas lymphoma cells accounted for 7% and 8% of the nucleated cells in the bone marrow smears from two IL-2-treated mice, these cells represented 21% and 24% of the nucleated cells in the bone marrow smears from two PBS-treated mice. No lymphoma cells were found in the bone marrow smears from mice in the cd T cells plus IL-2 treatment group (Figure 1d ).
Phenotypic and functional comparison of anti-cd TCR Ab-and PAM-expanded cd T cells
The quantity and quality of the transferred cells are important for adoptive immunotherapy. Therefore, we compared the proliferation and survival of cd T cells expanded by anti-cd TCR Ab with those expanded by PAM. Human peripheral blood cd T cells were expanded by anti-cd TCR Ab or PAM for 3 weeks. The purities, survival rates and expanding efficiencies at different time points (1, 2 and 3 weeks) were recorded and compared. Both strategies caused expansion of cd T cells at ,90% purity at the 3-week time point. Although the purity and survival rate of cd T cells expanded in response to Ab were lower than cells expanded by PAM during the first two weeks, they reached the same or even higher levels at 3 weeks. A similar expanding efficiency was observed in the Ab-and PAM-stimulated cd T cells during the entire culture process (Figure 2a) .
To determine the function-related phenotype and cytokine release profile of cd T cells during the expansion process, we analysed the Abor PAM-activated cd T cells at different time points. We found that culture time had little impact on the expression levels of most analysed molecules. The cytotoxic activities of the cd T cells expanded by both methods were determined as well. Consistent with the purity of cd T cells in the culture, the cytotoxicity of the cells expanded by both methods was gradually enhanced over time. The PAM-expanded cd T cells exhibited slightly stronger cytotoxic activity than the Ab-expanded cells at 1 week, probably resulting from their higher purity at that time. At 2 and 3 weeks, similar cytotoxic activity towards Daudi cells was observed (Figure 2d ).
Phenotypic and functional comparison of Ab-expanded Vd1 and Vd2 subsets
The most significant difference between the Ab-and PAM-expanded cd T cells was the presence of the Vd1 subset in the Ab expanded cells. To determine the differences between the Vd1 and Vd2 subsets, we compared their phenotypes and cytotoxicity at the end of the 2-week culture period.
The Vd1 and Vd2 subsets contained almost equal proportions of CD6 1 and NKG2D 1 cells, while the Vd1 subset contained more CD27 (Figure 3a) . The Vd1 subset contained fewer TNF-a-producing, but more IFN-c-producing cells than the Vd2 subset upon PMA/ionomycin stimulation. Cells in both subsets had similar CD107a and PD1 expression (Figure 3b) . To compare the cytotoxic activity between them, we purified each subset by magnetic bead separation at 2 weeks and tested their cytotoxicity against Daudi and K562 cells. As shown in Figure 3c , Vd1 and Vd2 subset exhibited similar cytotoxicity against these tumour cells.
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Vd1 T cells manifested a superior tendency to migrate towards CCL17 and CCL22, primarily via CCR4 Chemokines and chemokine receptors play vital roles in lymphocyte function in vivo. High levels of TARC/CCL17 (thymus-and activation-regulated chemokine) and MDC/CCL22 (macrophage-derived chemokine) have been detected in various lymphomas. In this study, the mRNA expression levels of CCL17 and CCL22 were determined in five lymphoma cell lines, the myeloma cell line RPMI 8226 and the chronic myelogenous leukaemia cell line K562. It was found that the non-Hodgkin's lymphoma cell line Daudi expressed a certain level of were killed. Blood films and bone marrow smears were prepared, fixed using absolute methanol, stained with May-Grunwald-Giemsa stain and evaluated by light microscopy for the presence of lymphoma cells. A manual differential count was performed in each blood film by counting 200 white blood cells per film. A differential count was also performed by counting 1000 nucleated cells in each bone marrow smear. Lymphoma cells, with large size, irregular nucleus shape and dark purple cytoplasm, were included in the differential counts. Although no lymphoma cells were detected in the blood films (magnification: 31000) from any of the three groups, lymphoma cells (indicated by the black arrows) were found in the bone marrow smears (magnification: 31000) from the PBS and IL-2 treatment groups. One representative microscopic view is shown. **P,0.01; ***P,0.005. PBS, phosphate-buffered saline; TCR, T-cell receptor.
Adoptive cd T cell Immunotherapy JH Zhou et al 38 CCL17 and that the Hodgkin's lymphoma cell line L-428 exhibited extremely high expression of CCL17 mRNA. Additionally, the Daudi cells and the cutaneous T lymphoma HuT-78 cells also expressed CCL22. In contrast, the lymphoma cell line Ramos (RA.1) and Jurkat cells had very low levels of CCL17 and CCL22 gene expression (Figure 4a ). It was meaningful that both chemokines were also detected in K562 and RPMI 8226 cells. The PCR results were further confirmed by ELISA testing of the cell culture supernatants (Figure 4b ). Both CCL17 and CCL22 are ligands for CCR4. CCL17 is also a ligand for CCR8. Therefore, we examined CCR4 and CCR8 expression in the Vd1 and Vd2 subsets. Our data showed that more Vd1 T cells expressed CCR4 and CCR8 than Vd2 T cells (Figure 4c) . The results of an in vitro migration assay showed that CCL17 and CCL22 had an apparent impact on the migration of cd T cells, especially Vd1 T cells (P,0.05 compared with Vd2 T cells). To determine whether CCR4 or CCR8 was responsible for recruitment, anti-CCR4 Ab-and anti-CCR8 Ab-mediated blocking assays were carried out. We found that the anti-CCR4 Ab could significantly block the chemoattraction caused by CCL17 and CCL22 in both the Vd1 and Vd2 subsets. In contrast, the anti-CCR8 Ab could only block CCL17 mediated chemotaxis but not CCL22-mediated chemotaxis (Figure 4d ).
Proliferation, phenotype and cytotoxicity of cd T-cells from the peripheral blood of lymphoma patients To test the feasibility of employing Ab-expanded cd T cells for lymphoma immunotherapy, we expanded cd T cells from peripheral blood drawn from 12 lymphoma patients. Peripheral blood cd T cells proliferated in response to immobilized anti-TCR cd Ab in all the patients. The purities of the expanded cd T cells at the end of a 2-week culture period ranged from 40% to 96%. Proliferation efficiencies, calculated by dividing the number of expanded to initial cd T cells, ranged from 100 to 700 (Figure 5a ). The expanded cells belonged to the Vd1 (25%-60%) or Vd2 (36%-80%) subsets. Most cells expressed NKG2D and CD6, and 54613% were CD27 2 CD45RA 2 . The expression of CD107a, granzyme B, TNF-a and IFN-c in the expanded cd T cells markedly increased following PMA/ionomycin stimulation. In contrast, PD1 expression remained low upon PMA/ionomycin treatment (Figure 5b) . All of the cd T cells showed some degree of cytotoxicity towards the lymphoma cell line Daudi (Figure 5c ). Consistent with the data from normal donors, significantly more Vd1 T cells were CCR4-or CCR8-positive (Figure 5d ).
DISCUSSION
In human peripheral blood, cd T cells account for only 1%-10% of CD3 1 T cells. According to their d-chain usage, cd T cells can be divided into two major groups, the Vd1 and Vd2 T cells. The Vd2 subset is dominant in the peripheral blood, whereas the Vd1 subset is frequently found in epithelial tissues and in epithelial tumourinfiltrating lymphocytes (TILs). 17 Neither subset responds to Figure 3 Phenotypic and functional comparisons of Vd1 and Vd2 subsets. PBMCs from four healthy donors were cultured in the presence of immobilized anti-cd TCR antibody for 2 weeks, then either the Vd1 or Vd2 subset was obtained via magnetic cell sorting, and the expression of CD6, NKG2D, CD27 and CD45RA (a), the expression of CD107a, PD1 and production of TNF-a and IFN-c without and with PMA/Ion restimulation (b), and the cytotoxic effects against Daudi and K562 cells (c) of both subsets were compared. *P,0.05. IFN, interferon; Ion, ionomycin; PBMC, peripheral blood mononuclear cell; PD1, programmed-death receptor 1; PMA, phorbol 12-myristate-13-acetate; TCR, T-cell receptor; TNF, tumour-necrosis factor.
Adoptive cd T cell Immunotherapy JH Zhou et al 40 peptide antigens presented by major histocompatibility complex. Instead, they can recognize non-peptide antigens, such as phosphoantigens 18 and stress-induced proteins such as MICA/B, 19 ULBPs, 20 heat shock proteins and F1F0-ATPase, 21 via TCR and/ or non-TCR receptors. In vitro and in vivo studies have demonstrated that human cd T cells can kill various haematological and solid tumour cells expressing these antigens. In addition to direct killing of tumour targets, cd T cells also display an anti-tumour effect in vivo by activating other innate cells and promoting the adaptive immune response. For example, recent data have demonstrated that cd T lymphocytes can induce robust natural killer cellmediated anti-tumour cytotoxicity. 22 Additionally, increasing evidence has demonstrated that cd T cells play an important role in the cross-talk between innate and adaptive immunity. cd T cells actively regulate the adaptive immune response through interactions with antigen presenting cells, such as dendritic cells. 23 They can even directly present antigens to adaptive immune cells. 24 Currently, most clinical studies are aimed at increasing the cd T 
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We have previously established conditions for expanding peripheral blood cd T cells with immobilized anti-cd TCR antibodies over a 2-week culture period. 16 The in vitro-expanded cd T cells displayed potent cytotoxicity against various tumours. In the present study, anti-cd TCR Ab-expanded cd T cells showed potent anti-tumour effects against various types of haematological cell lines, including the non-Hodgkin's lymphoma cell lines Daudi, Ramos (RA.1), HuT-78 and Jurkat, as well as the Hodgkin's lymphoma cell line L-428. Furthermore, they also demonstrated a potent anti-lymphoma effect in Daudi lymphoma-bearing nude mice, indicating the feasibility of this regimen for lymphoma treatment.
Phosphoantigens are widely used to stimulate cd T cells. Previous studies have shown that lymphoid malignancies can be recognized and killed by phosphoantigen-expanded cd T cells in animal models. 25, 26 Aminobisphosphonates, which inhibit the mevalonate pathway by reducing the activity of farnesyl pyrophosphate synthase, promote the intracellular accumulation of isopentenyl pyrophosphate, and activate cd T cells in vitro and in vivo. 5, 27 As one of the new-generation aminobisphosphonates, PAM was proven to be a more potent cd T cell stimulus. 5 Compared to PAM-activated cells, cd T cells stimulated by the anti-cd TCR Ab manifested a relatively delayed activation response, followed by a mild but sustained proliferation process. The Ab-expanded cells constantly expressed anti-tumour activityrelated biomolecules, including CD6, NKG2D, CD107a, TNF-a and IFN-c. Our data indicate that Ab stimulation supported a 3-week-long expansion with adequate purity and quantity without apparent function loss. In contrast, PAM stimulated rapid cd T-cell activation and proliferation. Although these seemingly rapidly activated cd T cells displayed similar proliferation and cytotoxic activity against tumour cells during the 3-week culture period, they produced less IFN-c than Ab-expanded T cells. It is noteworthy that IFN-c plays an important role in in vivo anti-tumour activity by enhancing the Th1 immune response. 28 Hence, this difference might make sense. In contrast, Ab-expanded cd T cells contained more CD27
2 CD45RA 2 cells and fewer CD27
1 CD45RA 2 cells than PAM-expanded cd T cells. It has been proposed that cd T cells differentiate in a sequence 15, 35 In the present study, expanded cd T cells expressed comparable levels of CD6 and NKG2D over the culture time.
PD1 is expressed on peripheral T and B lymphocytes upon activation. 36 It negatively regulates activated T cells upon interaction with its ligands PD-L1 and PD-L2. Many tumours, including lymphoma, express PD1 ligands. 37, 38 The PD1 ligand/PD1 signalling pathway mediates one of the tumour immune evasion strategies. [37] [38] [39] Following the initial activation, PD1 expression is transiently elevated, especially on Ab-expanded cells, in the first week. Fortunately, PD1 expression gradually decreased with time and reached a considerably low level over the next 2 weeks of the culture period.
It must be noted that only the peripheral Vd2, but not the Vd1 subset, can be expanded by phosphoantigens. In contrast, the anticd TCR Ab is a potent stimulus that could expand both Vd1 and Vd2 subsets. It has been reported that some MICA/B or ULBPs expressing malignant haematological cells were susceptible to Vd1 T cellmediated cytotoxicity. 15, 40 In this study, we found that the expanded Vd1 T cells contained relatively fewer TNF-a-, but more IFN-c-, producing cells upon PMA/ionomycin stimulation; however, they had similar levels of CD107a and PD1 expression and displayed comparable cytotoxic effects against Daudi cells and K562 cells as the Vd2 T cells. Recently, it was reported that both the Vd1 and Vd2 subsets could be expanded using concanavalin A 41 or anti-CD3 Ab. 42 Both of the protocols resulted in considerable percentages of the Vd1 and Vd2 subsets. However, because both concanavalin A and anti-CD3 Ab are unspecific activators of cd T cells, cd T cells must be purified before expansion. In contrast, according to our protocol, PBMCs can directly be expanded by anti-cd TCR Ab to obtain both the Vd1 and Vd2 subsets. This makes our protocol simple and easy to operate for most laboratories. It reduces costs and is more suitable for clinical use.
Recruiting effector lymphocytes to the tumour site is an essential prerequisite for an effective anti-tumour immune response. The migration of effector lymphocytes greatly depends on chemokines and their receptors. In this study, several lymphoma cell lines expressed CCL17 and/or CCL22. It has also been reported that high levels of CCL17 and CCL22 were detected in various tumours, such as lung cancer, 43 gastric cancer, 44 B-cell non-Hodgkin lymphoma, 45 Hodgkin's lymphoma 46 and peripheral T-cell lymphomas. 47 Among the lymphomas, CCL17 is specifically expressed in classical Hodgkin's lymphoma, 46, 48 while CCL22 is expressed in nodular lymphocyte-predominant Hodgkin9s lymphoma and B-cell non-Hodgkin's lymphoma. 49 Both CCL17 and CCL22 are ligands for CCR4, but CCL17 is also a ligand for CCR8. We found that significantly more Vd1 T cells expressed CCR4 and CCR8 than Vd2 T cells. CCL17 and CCL22 could significantly induce migration of Vd1 T cells, suggesting that Vd1 T cells have distinctive and non-redundant anti-lymphoma effects in vivo.
Importantly, peripheral blood cd T cells from all patients proliferated in response to immobilized anti-cd TCR Ab. Expanded cd T cells expressed function-related phenotype markers, such as CD107a and granzyme B, and released cytokines including TNF-a and IFN-c. Additionally, they showed potent cytotoxicity against the lymphoma cell line Daudi. Consistent with the results from healthy donors, significantly more Vd1 T cells expressed CCR4 and CCR8 than Vd2 T cells in lymphoma patients. It is noteworthy that Vd1 T cells constituted 25%-60% of the expanded cd T cells in lymphoma patients. Vd1 T cells will consequently be necessary in fighting against lymphoma in vivo. Therefore, adoptive transfer of anti-cd TCR Ab-expanded autologous cd T cells for the treatment of lymphoid malignancies is a feasible and promising strategy.
Currently, a phase I clinical trial carried out by our research group using anti-cd TCR Ab-expanded cd T cells for adoptive immune therapy for hepatocellular carcinoma has just been completed, and a phase II clinical trial is underway. Our present data indicate that Abexpanded cd T cells, which comprise both Vd1 and Vd2 subsets, can be an excellent candidate for adoptive immune therapy in patients with lymphoma. Further studies will focus on optimizing the current cd Tcell preparation, establishing individualized therapeutic regimens, and choosing the appropriate indications for the adoptive cd T-cell immunotherapy.
